Scientists are exploring gene editing as a way to correct trisomy at the cellular level. Using CRISPR-Cas9, researchers ...

In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...

Gene editing techniques may eventually allow trisomy to be treated at the cellular level, according to an in vitro ...

The future of medicine with CRISPR and CAR-T therapy, exploring ethical, societal, and accessibility challenges in healthcare ...

The evolution of cell and gene therapy is reshaping drug discovery, providing new hope for rare diseases and cancer through ...

Although plant cell-based bioproduction has advanced considerably during the past several years, certain elements remain largely unexplored.

Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

ERS Genomics ('ERS'), which was established to provide broad access to the foundational CRISPR/Cas9 intellectual property ...

CRISPR Therapeutics AG’s CRSP share price has surged by 14.33%, which has investors questioning if this is right time to sell ...